AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of $1.84 billion. The enterprise value is $1.83 billion.

Market Cap	1.84B
Enterprise Value	1.83B

Important Dates

The next estimated earnings date is Wednesday, August 5, 2026, after market close.

Earnings Date	Aug 5, 2026
Ex-Dividend Date	n/a

Share Statistics

AnaptysBio has 29.10 million shares outstanding. The number of shares has decreased by -3.66% in one year.

Current Share Class	29.10M
Shares Outstanding	29.10M
Shares Change (YoY)	-3.66%
Shares Change (QoQ)	-8.46%
Owned by Insiders (%)	2.96%
Owned by Institutions (%)	74.57%
Float	19.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	35.46
PS Ratio	7.91
Forward PS	21.61
PB Ratio	143.82
P/TBV Ratio	144.17
P/FCF Ratio	416.81
P/OCF Ratio	410.39
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 44.23, with an EV/FCF ratio of 414.75.

EV / Earnings	n/a
EV / Sales	7.87
EV / EBITDA	44.23
EV / EBIT	44.82
EV / FCF	414.75

Financial Position

The company has a current ratio of 7.58, with a Debt / Equity ratio of 21.76.

Current Ratio	7.58
Quick Ratio	7.49
Debt / Equity	21.76
Debt / EBITDA	6.33
Debt / FCF	62.91
Interest Coverage	0.49

Financial Efficiency

Return on equity (ROE) is -114.55% and return on invested capital (ROIC) is 7.61%.

Return on Equity (ROE)	-114.55%
Return on Assets (ROA)	6.78%
Return on Invested Capital (ROIC)	7.61%
Return on Capital Employed (ROCE)	14.17%
Weighted Average Cost of Capital (WACC)	8.75%
Revenue Per Employee	$2.23M
Profits Per Employee	-$257,567
Employee Count	104
Asset Turnover	0.62
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid $160,000 in taxes.

Income Tax	160,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +171.73% in the last 52 weeks. The beta is 0.41, so AnaptysBio's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+171.73%
50-Day Moving Average	59.49
200-Day Moving Average	48.68
Relative Strength Index (RSI)	62.60
Average Volume (20 Days)	559,006

Short Selling Information

The latest short interest is 4.63 million, so 15.92% of the outstanding shares have been sold short.

Short Interest	4.63M
Short Previous Month	4.82M
Short % of Shares Out	15.92%
Short % of Float	23.72%
Short Ratio (days to cover)	8.66

Income Statement

In the last 12 months, AnaptysBio had revenue of $232.39 million and -$26.79 million in losses. Loss per share was -$0.95.

Revenue	232.39M
Gross Profit	103.61M
Operating Income	40.80M
Pretax Income	-26.63M
Net Income	-26.79M
EBITDA	41.34M
EBIT	40.80M
Loss Per Share	-$0.95

Full Income Statement

Balance Sheet

The company has $286.46 million in cash and $277.36 million in debt, giving a net cash position of $9.10 million or $0.31 per share.

Cash & Cash Equivalents	286.46M
Total Debt	277.36M
Net Cash	9.10M
Net Cash Per Share	$0.31
Equity (Book Value)	12.75M
Book Value Per Share	0.44
Working Capital	274.41M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $4.48 million and capital expenditures -$69,000, giving a free cash flow of $4.41 million.

Operating Cash Flow	4.48M
Capital Expenditures	-69,000
Depreciation & Amortization	543,000
Net Borrowing	n/a
Free Cash Flow	4.41M
FCF Per Share	$0.15

Full Cash Flow Statement

Margins

Gross margin is 44.58%, with operating and profit margins of 17.56% and -11.53%.

Gross Margin	44.58%
Operating Margin	17.56%
Pretax Margin	-11.46%
Profit Margin	-11.53%
EBITDA Margin	17.79%
EBIT Margin	17.56%
FCF Margin	1.90%

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.66%
Shareholder Yield	3.66%
Earnings Yield	-1.46%
FCF Yield	0.24%

Analyst Forecast

The average price target for AnaptysBio is $87.09, which is 37.91% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$87.09
Price Target Difference	37.91%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (3Y)	10.48%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of 0.43 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.43
Piotroski F-Score	6